CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.12% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Madrigal Pharmaceuticals, Inc. (Extended hours) - MDGL CFD

334.95
4.04%
Market Trading Hours* (UTC) Opens on Monday at 09:00

Mon: 09:00 - 00:00

Tue - Thu: 00:00 - 01:00 09:00 - 00:00

Fri: 00:00 - 01:00 09:00 - 22:00

  • Summary
  • Historical Data
Trading сonditions
Spread 3.16
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023512 %
Charges from full value of position ($-0.24)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
-0.023512%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.00129 %
Charges from full value of position ($0.01)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
0.00129%
Overnight fee time 22:00 (UTC)
Min traded quantity 0.1
Currency USD
Margin 50.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 349.05
Open 347.98
1-Year Change 51.68%
Day's Range 334.95 - 353.95
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 21, 2025 334.95 -13.03 -3.74% 347.98 353.95 334.95
Feb 20, 2025 349.05 18.01 5.44% 331.04 350.63 331.04
Feb 19, 2025 343.34 1.47 0.43% 341.87 343.83 334.03
Feb 18, 2025 337.62 3.47 1.04% 334.15 342.05 329.96
Feb 14, 2025 335.76 -16.22 -4.61% 351.98 356.64 334.43
Feb 13, 2025 350.52 13.58 4.03% 336.94 352.30 334.31
Feb 12, 2025 338.78 9.84 2.99% 328.94 339.93 314.96
Feb 11, 2025 326.01 -7.43 -2.23% 333.44 338.93 326.01
Feb 10, 2025 335.20 -0.83 -0.25% 336.03 338.23 331.04
Feb 7, 2025 325.00 -7.94 -2.38% 332.94 334.95 325.00
Feb 6, 2025 329.95 -8.09 -2.39% 338.04 349.22 324.95
Feb 5, 2025 337.06 15.11 4.69% 321.95 341.84 312.50
Feb 4, 2025 321.95 -2.50 -0.77% 324.45 333.30 315.45
Feb 3, 2025 324.45 9.45 3.00% 315.00 334.50 315.00
Jan 31, 2025 330.95 -2.99 -0.90% 333.94 346.51 329.96
Jan 30, 2025 339.00 12.72 3.90% 326.28 341.77 318.99
Jan 29, 2025 324.99 -2.31 -0.71% 327.30 329.43 314.95
Jan 28, 2025 326.48 17.53 5.67% 308.95 328.14 308.10
Jan 27, 2025 308.95 -7.09 -2.24% 316.04 323.94 297.95
Jan 24, 2025 322.01 -19.42 -5.69% 341.43 341.43 321.95

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
Leverage
2:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Madrigal Pharmaceuticals, Inc. Company profile

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The Company’s lead product candidate, MGL-3196 (resmetirom), is a liver-directed, selective thyroid hormone receptor-ß (THR-ß) agonist for the treatment of non-alcoholic steatohepatitis (NASH)and heterozygous familial hypercholesterolemia (HeFH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and HeFH.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Madrigal Pharmaceuticals Inc revenues was not reported. Net loss increased 20% to $241.8M. Higher net loss reflects R & D increase of 11% to $194.5M (expense), G & A increase from $10M to $21.1M (expense), Stock-based Compensation in SGA increase of 36% to $16.2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$13.09 to -$14.63.

Equity composition

Common Stock $.0001 Par, 10/10, 100M auth., 42,166,779 issd. Insiders control approx. 37.8%. IPO: 2/06/07, 5M shares @ $10 per share by Bear, Stearns & Co. Inc.

Industry: Bio Therapeutic Drugs

200 Barr Harbor Dr Ste 400
WEST CONSHOHOCKEN
PENNSYLVANIA 19428-2978
US

People also watch

ETH/USD

2,779.27 Price
+5.290% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

Gold

2,936.56 Price
-0.110% 1D Chg, %
Long position overnight fee -0.0149%
Short position overnight fee 0.0067%
Overnight fee time 22:00 (UTC)
Spread 0.30

US100

21,594.40 Price
-2.120% 1D Chg, %
Long position overnight fee -0.0235%
Short position overnight fee 0.0013%
Overnight fee time 22:00 (UTC)
Spread 7.0

BTC/USD

96,674.75 Price
+1.390% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

Still looking for a broker you can trust?

Join the 690,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading